Search

Learn about the 21st Century Cures Act, which set out to improve the way providers share information to coordinate the care of their patients and to improve patients’ access to their own medical information.

… Friday, January 31, 2025 Transparency with patients and caregivers is a fundamental part of the mission of Memorial Sloan Kettering Cancer Center (MKS).  We have always believed that you should be empowered with the information you need to understand and manage your care.  The 21st Century Cures Act

MSK’s Chief Health Equity Officer, Carol Brown, MD, participated in a Fireside Chat on Health Equity for the Becker’s Healthcare Virtual Oncology Forum.

… Wednesday, September 8, 2021 MSK’s Chief Health Equity Officer, Carol Brown, MD , participated in a Fireside Chat on Health Equity for the Becker’s Healthcare Virtual Oncology Forum on July 26, 2021.  During the discussion, Dr. Brown spoke in-depth about addressing cancer health disparities that exist

These souped-up versions may help overcome some limitations of existing CAR T cells.

… Thursday, December 30, 2021 Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers. Now, scientists at Memorial

Meet Zhongmin Wang, a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), who has been awarded the 2021 Chairman’s Prize.

… Wednesday, September 22, 2021 Zhongmin Wang , a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2021 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Louis

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).

… Thursday, May 28, 2020 Dr. Charles Rudin Dr. Charles Rudin At the American Society of Clinical Oncology (ASCO) Virtual Scientific Program , Memorial Sloan Kettering (MSK) Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD , will present a study that found pembrolizumab addition to first-line

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

… Monday, December 1, 2014 Summary Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture. Since the late 1990s, when researchers first reported a technique to isolate and grow human embryonic stem cells, known as ES cells, in culture

Learn about diversity and inclusion at Memorial Sloan Kettering, as people from across MSK share their insights and personal experiences.

… Thursday, October 1, 2020 Memorial Sloan Kettering is committed to having conversations about discrimination, diversity, and inclusion, and creating change. People from across MSK share their personal experiences and insights. Louis Voigt Louis Voigt LOUIS VOIGT Associate Attending Department of Anesthesiology

Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.

… Friday, January 12, 2007 PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon, and brain. Researchers led by scientists at Memorial

New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward improving options for patients with early-stage, potentially indolent cancers.

… Monday, July 17, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers;

Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.

… Friday, September 13, 2019 It was a night of long hugs, standing ovations, well-earned tears, and “can you believe it?” stories, as Memorial Sloan Kettering hosted a lavish party to honor the patients, staff, and caregivers of MSK’s renowned Bone Marrow Transplant (BMT) Service . The event marked MSK